FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3148691346> ?p ?o ?g. }

• W3148691346 endingPage "2016" @default.
• W3148691346 startingPage "2006" @default.
• W3148691346 abstract "Background and purpose According to evidence-based clinical practice guidelines, patients presenting with disabling stroke symptoms should be treated with intravenous tissue plasminogen activator (IV tPA) within 4.5 h of time last known well. However, 25% of strokes are detected upon awakening (i.e., wake-up stroke [WUS]), which renders patients ineligible for IV tPA administered via time-based treatment algorithms, because it is impossible to establish a reliable time of symptom onset. We performed a systematic review and meta-analysis of the efficacy and safety of IV tPA compared with normal saline, placebo, or no treatment in patients with WUS using imaging-based treatment algorithms. Methods We searched MEDLINE, Web of Science, and Scopus between January 1, 2006 and April 30, 2020. We included controlled trials (randomized or nonrandomized), observational cohort studies (prospective or retrospective), and single-arm studies in which adults with WUS were administered IV tPA after magnetic resonance imaging (MRI)- or computed tomography (CT)-based imaging. Our primary outcome was recovery at 90 days (defined as a modified Rankin Scale [mRS] score of 0-2), and our secondary outcomes were symptomatic intracranial hemorrhage (sICH) within 36 h, mortality, and other adverse effects. Results We included 16 studies that enrolled a total of 14,017 patients. Most studies were conducted in Europe (37.5%) or North America (37.5%), and 1757 patients (12.5%) received IV tPA. All studies used MRI-based (five studies) or CT-based (10 studies) imaging selection, and one study used a combination of modalities. Sixty-one percent of patients receiving IV tPA achieved an mRS score of 0 to 2 at 90 days (95% confidence interval [CI]: 51%-70%, 12 studies), with a relative risk (RR) of 1.21 compared with patients not receiving IV tPA (95% CI: 1.01-1.46, four studies). Three percent of patients receiving IV tPA experienced sICH within 36 h (95% CI: 2.5%-4.1%; 16 studies), which is an RR of 4.00 compared with patients not receiving IV tPA (95% CI: 2.85-5.61, seven studies). Conclusions This systematic review and meta-analysis suggests that IV tPA is associated with a better functional outcome at 90 days despite the increased but acceptable risk of sICH. Based on these results, IV tPA should be offered as a treatment for WUS patients with favorable neuroimaging findings." @default.
• W3148691346 created "2021-04-13" @default.
• W3148691346 creator A5005116549 @default.
• W3148691346 creator A5006104199 @default.
• W3148691346 creator A5010931202 @default.
• W3148691346 creator A5011173721 @default.
• W3148691346 creator A5020824375 @default.
• W3148691346 creator A5023431700 @default.
• W3148691346 creator A5040356072 @default.
• W3148691346 creator A5040723744 @default.
• W3148691346 creator A5042517107 @default.
• W3148691346 creator A5052058659 @default.
• W3148691346 creator A5066759572 @default.
• W3148691346 creator A5068350431 @default.
• W3148691346 creator A5083967951 @default.
• W3148691346 creator A5087403596 @default.
• W3148691346 creator A5089145929 @default.
• W3148691346 creator A5089216410 @default.
• W3148691346 date "2021-04-15" @default.
• W3148691346 modified "2023-10-16" @default.
• W3148691346 title "Thrombolytic therapy for wake‐up stroke: A systematic review and meta‐analysis" @default.
• W3148691346 cites W1980882937 @default.
• W3148691346 cites W1990837723 @default.
• W3148691346 cites W1995184324 @default.
• W3148691346 cites W2015712245 @default.
• W3148691346 cites W2021593215 @default.
• W3148691346 cites W2026003444 @default.
• W3148691346 cites W2051801861 @default.
• W3148691346 cites W2055376941 @default.
• W3148691346 cites W2062047217 @default.
• W3148691346 cites W2070477650 @default.
• W3148691346 cites W2079377126 @default.
• W3148691346 cites W2084944797 @default.
• W3148691346 cites W2110792462 @default.
• W3148691346 cites W2112339078 @default.
• W3148691346 cites W2124354478 @default.
• W3148691346 cites W2126930838 @default.
• W3148691346 cites W2128968009 @default.
• W3148691346 cites W2131614813 @default.
• W3148691346 cites W2133514192 @default.
• W3148691346 cites W2148656951 @default.
• W3148691346 cites W2151682273 @default.
• W3148691346 cites W2159233098 @default.
• W3148691346 cites W2164763924 @default.
• W3148691346 cites W2181101160 @default.
• W3148691346 cites W2292308933 @default.
• W3148691346 cites W2319983832 @default.
• W3148691346 cites W2488254633 @default.
• W3148691346 cites W2497769229 @default.
• W3148691346 cites W2531269403 @default.
• W3148691346 cites W2616141209 @default.
• W3148691346 cites W2800924554 @default.
• W3148691346 cites W2803802119 @default.
• W3148691346 cites W2803840093 @default.
• W3148691346 cites W2804787963 @default.
• W3148691346 cites W2905405759 @default.
• W3148691346 cites W2911361393 @default.
• W3148691346 cites W2914889416 @default.
• W3148691346 cites W2944491145 @default.
• W3148691346 cites W2965474444 @default.
• W3148691346 cites W2970684805 @default.
• W3148691346 cites W2982303713 @default.
• W3148691346 cites W2997083169 @default.
• W3148691346 cites W3003827780 @default.
• W3148691346 cites W3006663802 @default.
• W3148691346 cites W3014244926 @default.
• W3148691346 cites W3102589670 @default.
• W3148691346 cites W4244267183 @default.
• W3148691346 doi "https://doi.org/10.1111/ene.14839" @default.
• W3148691346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33772987" @default.
• W3148691346 hasPublicationYear "2021" @default.
• W3148691346 type Work @default.
• W3148691346 sameAs 3148691346 @default.
• W3148691346 citedByCount "9" @default.
• W3148691346 countsByYear W31486913462021 @default.
• W3148691346 countsByYear W31486913462022 @default.
• W3148691346 countsByYear W31486913462023 @default.
• W3148691346 crossrefType "journal-article" @default.
• W3148691346 hasAuthorship W3148691346A5005116549 @default.
• W3148691346 hasAuthorship W3148691346A5006104199 @default.
• W3148691346 hasAuthorship W3148691346A5010931202 @default.
• W3148691346 hasAuthorship W3148691346A5011173721 @default.
• W3148691346 hasAuthorship W3148691346A5020824375 @default.
• W3148691346 hasAuthorship W3148691346A5023431700 @default.
• W3148691346 hasAuthorship W3148691346A5040356072 @default.
• W3148691346 hasAuthorship W3148691346A5040723744 @default.
• W3148691346 hasAuthorship W3148691346A5042517107 @default.
• W3148691346 hasAuthorship W3148691346A5052058659 @default.
• W3148691346 hasAuthorship W3148691346A5066759572 @default.
• W3148691346 hasAuthorship W3148691346A5068350431 @default.
• W3148691346 hasAuthorship W3148691346A5083967951 @default.
• W3148691346 hasAuthorship W3148691346A5087403596 @default.
• W3148691346 hasAuthorship W3148691346A5089145929 @default.
• W3148691346 hasAuthorship W3148691346A5089216410 @default.
• W3148691346 hasConcept C121332964 @default.
• W3148691346 hasConcept C126322002 @default.
• W3148691346 hasConcept C127413603 @default.
• W3148691346 hasConcept C17744445 @default.

• next